Why CA2+ antagonists will be most useful before or during myocardial ischaemia and not after infarction has been established

1986

European Heart Journal , Volume 7 - Issue 4 p. 270- 278

Additional Metadata
Keywords	0 (Adrenergic beta-Antagonists), 0 (Calcium Channel Blockers), 21829-25-4 (Nifedipine), Adrenergic beta-Antagonists/administration & dosage, Angina, Unstable/drug therapy, Animals, Calcium Channel Blockers/pharmacology/therapeutic use, Comparative Study, Coronary Disease/drug therapy/pathology/physiopathology, Coronary Vessels/drug effects, Drug Therapy, Combination, Heart/drug effects/physiopathology, Human, Myocardial Infarction/drug therapy, Myocardium/metabolism/ultrastructure, Nifedipine/pharmacology, Time Factors
Persistent URL	hdl.handle.net/1765/4209
Journal	European Heart Journal
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Hugenholtz, P., Serruys, P., Fleckenstein, A., & Nayler, W. (1986). Why CA2+ antagonists will be most useful before or during myocardial ischaemia and not after infarction has been established. European Heart Journal, 7(4), 270–278. Retrieved from http://hdl.handle.net/1765/4209

Additional Files
Publishers version Final Version

Publication